

Ain Shams University
Faculty of Pharmacy
Pharmacology and Toxicology
Department



**Study on the potential neuroprotective effect of
tetramethylpyrazine in rotenone-induced model of Parkinson's
disease in rats**

A thesis submitted for the partial fulfillment of requirements for the degree of
Doctor of Philosophy (PhD) in Pharmaceutical Sciences
(Pharmacology & Toxicology)

By

Haidy Effat Michel Koressa

M.Sc. degree in Pharmaceutical Sciences, Pharmacology and Toxicology (2013)
Assistant Lecturer of Pharmacology and Toxicology,
Faculty of pharmacy, Ain Shams University

Under the supervision of

Prof. Dr. Ahmed Mohey Eldin A. Tawab

Professor of Pharmacology, Faculty of Medicine, Ain Shams University

Dr. Mariane George Tadros

Associate Professor of Pharmacology and Toxicology,
Faculty of Pharmacy, Ain Shams University.

Dr. Ahmed Esmat Abdel-Razek

Lecturer of Pharmacology and Toxicology,
Faculty of Pharmacy, Ain Shams University.

Faculty of Pharmacy
Ain Shams University
(2016)

Acknowledgements

Acknowledgements can never be made to all those who have nourished my intellectual life. Still I must try to give credit where credit is due.

Above all, utmost appreciation and gratitude is to the Almighty God for the divine intervention in the academic endeavor.

While carrying out my research, I have been helped by generous professors who spared no effort to give me a hand. Without their painstaking effort and unstinted help, this research would have been impossible.

I am greatly thankful to my great Professor and Thesis advisor, Ahmed Mohey Eldin A. Tawab, Professor of Pharmacology , Department of Pharmacology, Faculty of Medicine, Ain Shams University, for his indispensable help throughout the whole thesis work as well as his unwavering guidance, continuous support and positive insights.

I am also greatly thankful to Dr. Mariane George Tadros, Associate Professor of Pharmacology and Toxicology, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, for her indispensable help throughout the whole Thesis work as well as her continuous guidance, and support.

I would like to thank Dr. Ahmed Esmat, lecturer of Pharmacology and Toxicology, Department of Pharmacology and Toxicology, Faculty of

Pharmacy, Ain Shams University, for his continuous help and support throughout the whole thesis work, especially in the western blot technique.

I would like to thank Dr. Adel Bakir, Professor of Pathology, Faculty of Veterinary Medicine, Cairo University, for his great effort in accomplishing the histological investigation.

I would like to thank Mr. Moussa Hussein and Mr. Mohamed Amin, The National Cancer Institute, Cairo University, for his effort in staining the slides for immunohistochemical investigations.

I would like also to thank my dear colleagues Esther Tharwat, Eman Mantawy and Diana Magdy, Department of Pharmacology and Toxicology, Ain Shams University, for their generous help and support.

It is my greatest pleasure to convey my deepest thanks to all my Professors, Doctors and colleagues in the department of Pharmacology and Toxicology, Ain Shams University, for providing me knowledge and experiences.

Finally, I would like to express my deep gratefulness and thanks to my family for their continuous moral, emotional and financial support.

List of Contents

Subject	Page
Introduction	1
I- Parkinson's Disease (PD)	1
I-1: Background	1
I-2: Diagnosis of PD	2
I-3: Epidemiology of PD	4
I-4: Disease frequency	5
I-5: Lifestyle factors and PD	8
I-6: Pathophysiology of PD	18
I-7: Neurotoxin-based models of PD	29
I-8: Medical management of PD	40
I-9: Concluding remarks	46
II- Tetramethylpyrazine (TMP)	47
II-1: Pharmacodynamics	48
II-2: Pharmacokinetics	56
Aim of the work	59
Materials and Methods	61
I- Experimental Design	61
II- Animals	64
III- Materials	64
IV- Methods	73
V-Statistical analysis	103

Results	104
Discussion	157
Summary and Conclusions	168
References	175
Arabic summary	

List of Abbreviations

3-MT	3-Methoxytramine
6-OHDA	6-Hydroxydopamine
Ab	Antibody
ABB	Antibody binding buffer
ALT	Alanine aminotransferase
ASK1	Apoptosis signal-regulating kinase 1
AST	Aspartate aminotransferase
A β	Amyloid β peptide
BBB	Blood-brain barrier
BCA	Bicinchoninic acid
Blk	Blank
BMI	Body mass index
BNIP3	Bcl-2/adenovirus E1B 19kDa interacting protein 3
CI	Confidence interval
COMT	Catechol-O-methyl-transferase
COX2	Cyclooxygenase 2
CXCR4	Chemokine (C-X-C motif) receptor 4
DA	Dopamine agonists
DAMP	Damage-associated molecular patterns
DOPAC	Dihydroxyphenylacetic acid
ERK	extracellular signal-regulated kinase
GCLc	Catalytic subunit of c-glutamylcysteine ligase
HIF-1 α	Hypoxia-inducible factor-1 α

HMGB1	High-mobility group box-1 protein
HO-1	Heme oxygenase-1
HVA	Homovanillic acid
IFN- γ	Interferon- γ
IGFBP3	Insulin growth factor binding protein 3
iNOS	Inducible nitric oxide synthase
JNK	c-jun N-terminal kinase
LBs	Lewy bodies
L-DOPA	3,4 Dihydroxy-L-phenylamine
MAOI	Monoamine oxidase inhibitor
MAPK	Mitogen-activated protein kinase
MDR	Multidrug resistance
MPP ⁺	1-Methyl-4-phenylpyridinium
MPTP	1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
MSA	Multiple system atrophy
NF- κ B	Nuclear Factor kappa B
NO	Nitric oxide
NOX2	NADPH oxidase 2
Nrf2	Nuclear factor erythroid 2-related factor 2
NSB	Non-specific binding
OHSCs	Organotypic hippocampal slice cultures
PD	Parkinson's disease
PET	Positron emission tomography
PGC-1 α	Peroxisome proliferator-activated receptor-c coactivator-1 α

PIC	Protease inhibitor cocktail
pNA	p-nitroaniline
POAG	Primary open-angle glaucoma
REM	Rapid eye movement
ROS	Reactive oxygen species
SDF-1	Stromal cell-derived factor-1
SNpc	Substantia nigra pars compacta
SOD	Superoxide dismutase
SPECT	Single-photon emission computed tomography
TEMED	Tetramethylethylenediamine
TLR4	Toll-like receptor-4
TMB	Tetramethylbenzidine
TMP	Tetramethylpyrazine
TNF- α	Tumor necrosis factor
UPDRS	Unified Parkinson's disease rating scale
VEGF	Vascular endothelial growth factor

List of Figures

Figure Number	Figure Title	Page
i	Locations of PD pathology	19
ii	Possible mechanisms responsible for dopaminergic neurodegeneration in PD	22
iii	Oxidation of dopamine	23
iv	The neuroinflammatory and oxidative stress response in PD	26
v	Comparison of the chemical structures of 6-hydroxydopamine (6-OHDA) and dopamine	29
vi	The chemical structures of MPTP and MPP+	32
vii	The chemical structure of Paraquat	33
viii	The chemical structure of rotenone	34
ix	Mechanism of action of neurotoxins used to model Parkinson's disease	39
x	Pharmacological treatment options of PD	40

xi	Chemical structure of TMP	47
xii	Experimental design	63
xiii	Locomotor activity detector	72
1	Standard calibration curve for protein	80
xiv	Schematic representation for Nrf2 assay	88
2	Standard calibration curve for Nrf2	92
3	Standard calibration curve for HO-1	97
4	Standard calibration curve for pNA	102
5	Effects of different doses of TMP on rotenone-induced catalepsy in rats (bar test)	106
6	Effects of different doses of TMP on rotenone-induced catalepsy in rats (grid test)	107
7	Effects of different doses of TMP on rotenone-induced kypokinesia in rats	110
8	Representative photomicrographs of H&E-stained rat midbrain sections	112

9	Representative photomicrographs of H&E-stained rat whole striatal sections	113
10	Representative photomicrographs of toluidine-blue stained rat midbrain sections	115
11	Representative photomicrographs of toluidine-blue stained rat striatal sections	116
12	Quantitative analysis of midbrain and striatal neuronal degeneration calculated as the percentage of degenerated neurons in comparison to total neurons	117
13	Immunohistochemical staining of midbrain TH positive cells of the control group, rotenone-treated group, TMP (10mg/kg) + rotenone-treated group, TMP (20mg/kg) + rotenone-treated group, TMP (40mg/kg) + rotenone-treated group and TMP-alone treated group. (200X)	119
14	Immunohistochemical staining of striatal TH positive cells of the control group, rotenone-treated group, TMP (10mg/kg) + rotenone-treated group, TMP (20mg/kg) + rotenone-treated group, TMP (40mg/kg) + rotenone-treated group and TMP-alone treated group. (200X)	120
15	Quantitative image analysis for TH immunohistochemical staining expressed as mean area% (A%)	122
16	Immunohistochemical staining of midbrain α -synuclein positive cells of the control group, rotenone-treated group, TMP (10mg/kg) + rotenone-treated group, TMP (20mg/kg) + rotenone-treated group, TMP (40mg/kg) + rotenone-treated group and TMP-alone treated	124

	group. (200X)	
17	Immunohistochemical staining of striatal α -synuclein positive cells of the control group, rotenone-treated group, TMP (10mg/kg) + rotenone-treated group, TMP (20mg/kg) + rotenone-treated group, TMP (40mg/kg) + rotenone-treated group and TMP-alone treated group. (200X)	125
18	Quantitative image analysis for immunohistochemical staining of α -synuclein expressed as mean area% (A%)	127
19	Effect of TMP on caspase-3 activity in rats subjected to chronic rotenone administration expressed as percentage of control group.	131
20	Western blot analysis of midbrain and striatal Bax/Bcl2 ratio	133
21	Immunohistochemical staining of midbrain NF- κ B positive cells of the control group, rotenone-treated group, TMP (20mg/kg) + rotenone-treated group and TMP-alone treated group. (200X)	135
22	Immunohistochemical staining of striatal NF- κ B positive cells of the control group, rotenone-treated group, TMP (20mg/kg) + rotenone-treated group and TMP-alone treated group. (200X)	136
23	Quantitative image analysis for immunohistochemical staining of midbrain and striatal NF- κ B expressed as mean area% (A%)	138
24	Immunohistochemical staining of midbrain COX-2 positive cells of the control group, rotenone-treated group, TMP (20mg/kg) + rotenone-treated group and TMP-alone treated	140

	group. 200X	
25	Immunohistochemical staining of striatal COX-2 positive cells of the control group, rotenone-treated group, TMP (20mg/kg) + rotenone-treated group and TMP-alone treated group. 200X	141
26	Quantitative image analysis for immunohistochemical staining of midbrain and striatal COX2 expressed as mean area% (A%)	143
27	Immunohistochemical staining of midbrain iNOS positive cells of the control group, rotenone-treated group, TMP (20mg/kg) + rotenone-treated group and TMP-alone treated group. 200X	145
28	Immunohistochemical staining of striatal iNOS positive cells of the control group, rotenone-treated group, TMP (20mg/kg) + rotenone-treated group and TMP-alone treated group. 200X	146
29	Quantitative image analysis for immunohistochemical staining of midbrain and striatal iNOS expressed as mean area% (A%)	148
30	Western blot analysis of midbrain and striatal DJ-1 expression	150
31	Effect of TMP on Nrf2 level in rats subjected to chronic rotenone administration expressed as percentage of control group	153
32	Effect of TMP on HO-1 level in rats subjected to chronic rotenone administration expressed as percentage of control group	156

List of tables

Table Number	Table Title	Page
i	Pharmacokinetic analysis of tetramethylpyrazine in rat blood and brain	57
ii	Toxicity of tetramethylpyrazine	58
1	Effects of different doses of TMP on rotenone-induced catalepsy in rats	105
2	Effects of different doses of TMP on rotenone-induced hypokinesia	109
3	Effect of different doses of TMP on TH expression in the midbrains and striata of rotenone-treated rats, expressed as A%	121
4	Effect of different doses of TMP on α -synuclein expression in the midbrains and striata of rotenone-treated rats, expressed as A%	126
5	Effect of TMP on caspase-3 activity (nmol/min/mg protein) in the midbrains and striata of rotenone-treated rats	130
6	Effect of TMP on NF- κ B expression in the midbrains and striata of rotenone-treated rats, expressed as A%	137
7	Effect of TMP on COX2 expression in the midbrains and striata of rotenone-treated rats, expressed as A%	142
8	Effect of TMP on iNOS expression in the midbrains and striata of rotenone-treated rats,	147